
    
      This is a randomized, double blind, parallel group, multicenter, outpatient study evaluating
      the efficacy and safety of flexibly-dosed dasotraline in adults with BED using dasotraline
      (4, 6, and 8 mg/day) versus placebo over a 12 week treatment period.
    
  